A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

NCT01810939 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease (CKD)
Hyperkalemia (HK)

Interventions

DRUG: Patiromer
DRUG: Placebo

Sponsor

Relypsa, Inc.